A critical appraisal of biomarkers in prostate cancer
A number of urine and blood-based biomarker tests have been described for prostate cancer, although to date there has only been a limited exploration of the methodology behind the validation studies that underpin these tests.
In this review, a selection of commercially available urine and blood-based biomarker tests for prostate cancer are described, and the underlying key validation studies for each test are critically appraised using the Standards for Reporting Diagnostic Accuracy (STARD) 2015 statement.
The ExoDx Prostate Intelliscore, SelectMDx, Progensa PCA3, Mi-Prostate Score, 4K Score, and Prostate Health Index (PHI) tests were reviewed. Most of the validation studies supporting these tests perform exploratory analyses to determine cut-off values in a post hoc manner, comprise cohorts that are primarily Caucasian, report receiver operating characteristic curves that combine the biomarker’s result with established clinical nomograms and are based on a reference standard (prostate biopsy) that lacks central pathology review. Deficiencies in STARD reporting guidelines include frequent failure to provide a published study protocol, prospective study registration in a registry, a flow diagram, justification for sample size determination, a discussion of adverse events with testing, and information on how missing or indeterminate test results should be managed.
Key validation studies that support many commercially available urine and blood-based biomarkers for prostate cancers have deficiencies in transparency based on STARD reporting guidelines, and limitations in methodology must be considered when deciding when these tests should be applied in clinical practice.
KeywordsProstate cancer Biomarkers Genomic tests STARD Diagnostic test accuracy Critical appraisal
VMN: data collection, analysis, and manuscript writing/editing.
Compliance with ethical standards
Conflict of interest
Vikram Narayan has no conflicts of interest to disclose.
- 16.Denzer K, Kleijmeer MJ, Heijnen HF et al (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113(Pt 19):3365–3374Google Scholar
- 21.Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4%3c361:AID-SIM168%3e3.0.CO;2-4 CrossRefGoogle Scholar
- 26.Cornu J-N, Cancel-Tassin G, Egrot C et al (2013) Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 73:242–249. https://doi.org/10.1002/pros.22563 CrossRefGoogle Scholar
- 29.Vickers AJ, Cronin AM, Roobol MJ et al (2010) A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 16:3232–3239. https://doi.org/10.1158/1078-0432.CCR-10-0122 CrossRefGoogle Scholar
- 33.Mikolajczyk SD, Marker KM, Millar LS et al (2001) A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61:6958–6963Google Scholar
- 34.Catalona WJ, Partin AW, Sanda MG et al (2011) A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655. https://doi.org/10.1016/j.juro.2010.12.032 CrossRefGoogle Scholar